M&A Deal Summary

MaxCyte Acquires SeQure Dx

On January 30, 2025, MaxCyte acquired life science company SeQure Dx for 5M USD

Acquisition Highlights
  • This is MaxCyte’s 1st transaction in the Life Science sector.
  • This is MaxCyte’s largest (disclosed) transaction.
  • This is MaxCyte’s 1st transaction in the United States.
  • This is MaxCyte’s 1st transaction in Massachusetts.

M&A Deal Summary

Date 2025-01-30
Target SeQure Dx
Sector Life Science
Buyer(s) MaxCyte
Deal Type Add-on Acquisition
Deal Value 5M USD

Target

SeQure Dx

Waltham, Massachusetts, United States
SeQure Dx is a gene editing safety analytics company advancing cell and gene therapies from discovery to patient. With a robust portfolio of assays, including the innovative ONE-seq and GUIDE-seq platforms, it provides comprehensive off-target risk assessment solutions for gene editing, spanning from early discovery through IND submission. SeQure Dx is based in Waltham, Massachusetts.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

MaxCyte

Rockville, Maryland, United States

Category Company
Founded 1998
Sector Life Science
Employees114
Revenue 39M USD (2024)
DESCRIPTION

MaxCyte discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. MaxCyte was founded in 1998 and is headquartered in Rockville, Maryland.


DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: Massachusetts M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2025 M&A 1 of 1
Size (of disclosed) 1 of 1